Philip Ashton-Rickardt

Philip Ashton-Rickardt

Director Técnico/Científico/I+D en SIGILON THERAPEUTICS, INC. .
62 años
Consumer Services
Health Technology

Perfil

Philip Ashton-Rickardt was the founder of Smith Therapeutics, Inc. (founded in 2017), where he held the titles of President, CEO, Secretary & Director until 2019.
He is currently the Chief Scientific Officer at Sigilon Therapeutics, Inc. (since 2021).
Previously, he worked as the Chairman of Immunology at Imperial College London, Senior Vice President of Immunology at AZTherapies, Inc. (2019-2021), and Associate Professor at The University of Chicago (1995-2006).
Dr. Ashton-Rickardt obtained his doctorate degree from The University of Edinburgh and his undergraduate degree from King's College London.

Cargos activos de Philip Ashton-Rickardt

EmpresasCargoInicio
SIGILON THERAPEUTICS, INC. Director Técnico/Científico/I+D 14/06/2021

Antiguos cargos conocidos de Philip Ashton-Rickardt.

EmpresasCargoFin
Corporate Officer/Principal 01/06/2021
Fundador 31/10/2019
Corporate Officer/Principal 01/06/2006
Corporate Officer/Principal -
Ver el detalle de la experiencia de Philip Ashton-Rickardt.

Formación de Philip Ashton-Rickardt.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

95

Relaciones de 1er grado

7

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas7

Health Technology

Consumer Services

Consumer Services

Consumer Services

Consumer Services

Health Technology

Health Technology

  1. Bolsa de valores
  2. Insiders
  3. Philip Ashton-Rickardt
40% de descuento. Las herramientas más útiles solo para suscriptores: ¡descubre las mejores inversiones del futuro!
d
:
:
APROVECHAR LA PROMOCIÓN